Clinical Trials
27 trialsNCT04280081 2026-04-24
LIBRETTO-321
Eli Lilly and Company
Phase 2 Active not recruiting
NCT01298323 2026-04-17
Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment
Sanofi
Phase 3 Completed
NCT03157128 2026-04-16
LIBRETTO-001
Eli Lilly and Company
Phase 1/2 Active not recruiting
NCT04211337 2026-03-19
LIBRETTO-531
Eli Lilly and Company
Phase 3 Active not recruiting
NCT03899792 2026-01-06
LIBRETTO-121
Eli Lilly and Company
Phase 1/2 Active not recruiting
NCT01496313 2025-10-03
To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer
Sanofi
Phase 4 Completed
NCT00410761 2025-09-24
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
Sanofi
Phase 3 Completed
NCT01896479 2025-09-02
EXAMINER
Exelixis
Phase 4 Active not recruiting
NCT03037385 2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2 Completed
NCT01856920 2024-07-09
QUILT-3.006 for Recurrent Medullary Thyroid Cancer
NantCell, Inc.
Phase 2 Completed
NCT04161391 2024-06-13
Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations
Turning Point Therapeutics, Inc.
Phase 1/2 Terminated
NCT05675605 2024-01-30
A Study of TY-1091 in Patients With Advanced Solid Tumors
TYK Medicines, Inc
Phase 1/2 Unknown
NCT04760288 2024-01-05
AcceleRET-MTC
Hoffmann-La Roche
Phase 3 Withdrawn
NCT03780517 2023-10-30
Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors
Boston Pharmaceuticals
Phase 1 Completed
NCT05830500 2023-07-25
Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 4 Recruiting
NCT04787328 2022-02-23
A Study of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Unknown
NCT00704730 2021-04-20
EXAM
Exelixis
Phase 3 Completed
NCT02709889 2020-10-19
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
AbbVie
Phase 1/2 Terminated
NCT02586350 2019-05-21
Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2/3 Completed
NCT02114658 2017-08-03
Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients
Bayer
Phase 2 Completed
NCT01539655 2017-05-02
Vandetanib
Sanofi
Phase 1 Completed
NCT00358956 2017-01-30
A Study To Assess ZD6474 (ZACTIMAâ„¢) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
Sanofi
Phase 2 Completed
NCT01661179 2016-12-05
Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma
Sanofi
Phase 1/2 Completed
NCT00096083 2013-10-23
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
Delcath Systems Inc.
Phase 2 Completed
NCT00121628 2013-10-09
A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer
Amgen
Phase 2 Completed
NCT00215605 2013-02-27
Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies
Exelixis
Phase 1 Completed
NCT01739634 2012-12-03
The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer
Salient Pharmaceuticals Incorporated
Phase 1/2 Unknown